Survival of a cohort of patients with Intermediate and advanced gall bladder cancer treated with a prospective therapeutic protocol

Acta Cirurgica Brasileira

Carlos Manterola²  Manuel Vial¹  Juan Carlos Roa¹ 

[1] ,Universidad de La Frontera Faculty of Medicine Department of SurgeryTemuco,Chile

关键词: Gallbladder Neoplasms;    Hepatectomy;    Chemotherapy;    Adjuvant;    Neoplasias da Vesícula Biliar;    Hepatectomia;    Quimioterapia Adjuvante;   

DOI  :  10.1590/S0102-86502010000300003

来源: SciELO

【 摘 要 】

PURPOSE: To evaluate the results of a prospective therapeutic protocol with long-term follow up in terms of survival rates in a cohort of patients treated with Intermediate and Advanced GBC (GBC). METHODS: Prospective cohort of patients with intermediate and advanced stages of GBC treated between 1996 and 2006. All cases were treated with a partial hepatic segmentectomy on segments IVb and V and a regional lymph node dissection and six cycles of out-patient chemotherapy (5-FU and leukovorin). With an average follow-up of 31.5 months, the morbidity, operative mortality, hepatic and lymphatic infiltration and actuarial survival were measured. Descriptive statistics were applied as well as bivariate analysis applying Fisher's exact test and non-parametrical tests and Kaplan Meier survival curves. Also logistic regression and proportional risk of Cox were applied. RESULTS: 40 patients were included in this protocol, with an average age of 59.5 years (40-85 years), of which 28 were women (70%). Depth of wall infiltration: muscular 8 patients (20%), subserosal 12 patients (30%), serosal 12 patients (30%) and perivesicular adipose tissue 8 patients (20%). The series morbidity was 27.5%. There was no operative mortality. The chemotherapy was well tolerated. The overall actuarial survival in the series was 50% at 60 months. CONCLUSION: Our protocol treatment has morbidity, mortality and survival rates similar to previously reported series.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License